The NRS 2002 trigger list is missing the largest new rosacea trigger of the decade.

What was new in the post-2020 dataset

The canonical patient-survey on rosacea triggers is the National Rosacea Society's 2002 study of 1,066 patients. It established the trigger-frequency ranking that still anchors most patient-facing rosacea content: sun exposure first, emotional stress second, hot weather third, and so on down to certain fruits and dairy at the bottom.

The 2002 list is solid for what it covers, but it predates by two decades the largest single new rosacea-relevant event of the modern era: the COVID-19 pandemic. Patients infected with SARS-CoV-2 in 2020 and after were not represented in the 2002 cohort, and neither were patients who received COVID-19 vaccines from late 2020 onward. The trigger field that captures SARS-CoV-2 infection or vaccination simply did not exist in the 2002 framework, because the events did not.

The post-2020 dermatology literature has been catching up. A retrospective study from 2023 (Liu et al., Front Med 2023, accessible at PMC10581019) followed a cohort of rosacea patients through the post-COVID period and reported that 34 percent experienced post-COVID exacerbation of their rosacea symptoms. A more recent 2025 cross-sectional study published in Acta Dermato-Venereologica found that 28.8 percent of rosacea patients reported post-infection exacerbation and 15.4 percent reported post-vaccination exacerbation (the cross-sectional study at PubMed 40908756).

These are not small numbers. A trigger that affects roughly 1 in 3 rosacea patients during the relevant exposure window is comfortably above the threshold of the trigger taxonomy and well above many of the Tier A triggers on the canonical list. The NRS 2002 framework, last revisited in incremental updates, does not have a place for it.

What the published studies actually report

Read the two studies and the patterns they describe converge on a similar set of findings.

The Liu 2023 retrospective followed 87 rosacea patients across the post-COVID window in a single dermatology practice setting. Of the 87, 30 (34 percent) reported clinical exacerbation of their rosacea following SARS-CoV-2 infection. The exacerbation typically presented within several weeks of the acute infection, included worsening of erythema and an increase in inflammatory lesions (papules and pustules), and was distinct from the brief post-fever flushing some patients had during the acute illness. The exacerbation did not always remit fully on the patient's previous baseline timeline; some patients had a new, higher baseline severity that persisted.

The 2025 cross-sectional study (a larger cohort, published in Acta Dermato-Venereologica) distinguished between post-infection and post-vaccination exacerbation patterns. Post-infection exacerbation was reported by 28.8 percent of the rosacea cohort, consistent with the Liu 2023 figure adjusted for the cross-sectional rather than longitudinal design. Post-vaccination exacerbation was reported by 15.4 percent of the cohort, lower than the post-infection figure but well above background.

The two studies use different designs (single-practice retrospective vs. cross-sectional survey) and different populations, but converge directionally: both SARS-CoV-2 infection and COVID-19 vaccination are associated with rosacea exacerbation in a meaningful subset of patients, with infection consistently producing the larger effect.

Why this matters mechanistically

The mechanistic story for why a respiratory viral infection or vaccination would exacerbate a skin condition is plausible at multiple levels, even though the specific pathway for rosacea is still being worked out.

The candidate mechanisms in the published discussions:

- Systemic inflammatory response. Both SARS-CoV-2 infection and the mRNA vaccines induce systemic inflammation (cytokine release, increased pro-inflammatory cytokines for days to weeks). Rosacea's pathogenesis is partly an inflammatory amplification disorder; a transient elevation in systemic inflammation would be expected to push the disease toward more active phenotypes. - Innate immune activation. Rosacea is associated with elevated cathelicidin LL-37 activity at baseline. Viral infections and adjuvanted vaccines both increase TLR-mediated innate immune signaling. The pathway connecting TLR activation to LL-37 elevation in rosacea is documented; the inference that an infection or vaccination could amplify this pathway is short. - Microvascular endothelial effects. SARS-CoV-2 has documented endothelial effects in the systemic vasculature (long-COVID literature on microvascular dysfunction). Rosacea has a vascular component; an endothelial-effect from the virus would be expected to interact with the rosacea-prone facial vasculature. - Mast cell sensitization. Viral infections sensitize mast cells in several tissues. Rosacea has documented mast-cell involvement. The sensitization story is plausible and partially supported in the broader long-COVID dermatology literature.

None of these mechanisms is exclusive of the others, and none has been definitively isolated as the primary driver. The directional signal is that SARS-CoV-2 infection and, to a lesser extent, COVID-19 vaccination push the rosacea-relevant inflammatory machinery toward higher activity. The patient-level outcome is the exacerbation pattern the studies describe.

What this means for trigger taxonomies

The post-COVID rosacea wave is a worked example of why a trigger taxonomy needs to be a living document, not a static list inherited from 2002.

The NRS 2002 framework gets several decisions right that are worth preserving (the broad bucket categories, the patient-survey methodology, the absence of strong claims beyond what the data supports). What it does not have is a mechanism for incorporating new trigger evidence as it emerges. There is no published 2024 or 2025 NRS replacement of the 2002 list with updated categories; the consumer rosacea content ecosystem has mostly continued to cite the 2002 figures without acknowledging the 23 years of new evidence behind them.

A tracker that codifies the 2002 list as default chips and does not surface the post-2020 evidence is shipping the literature as it stood before the pandemic. A patient using such a tracker has no way to log SARS-CoV-2 infection or COVID-19 vaccination as a trigger; the field for the trigger does not exist in the data model. The patient's exacerbation history, if they have it, ends up in the free-text notes field, which is exactly the data shape the literature on patient-tracker handoffs identifies as the noise category.

The right shape for the trigger taxonomy is a versioned, growing list. The Tier A canonical triggers (sun, hot drinks, alcohol with sub-tags, etc.) stay as the default chips. Emerging trigger evidence (post-COVID exacerbation, hormonal cycle phase, sleep deprivation, others) lives in the Tier B opt-in category until either the evidence consolidates to Tier A or the trigger turns out to be patient-individual enough that Tier C is the right home. The tier labels carry the evidence framing; the patient sees what is well-established and what is emerging.

How Skinframe handles the COVID trigger

Skinframe records SARS-CoV-2 infection and COVID-19 vaccination as Tier B emerging-trigger fields in the daily log.

The fields are off by default and opt-in for patients who want to track them. When the patient turns them on, the log adds:

- SARS-CoV-2 infection, as a one-time-per-event field. The patient logs the approximate infection date; the correlation engine tracks rosacea-severity trajectory in the weeks following. - COVID-19 vaccination, as a per-dose field. The patient logs each vaccination date (initial series, boosters); the correlation engine tracks the trajectory similarly. - General severe-illness flag, for any illness severe enough to be tracker-relevant. This generalizes the COVID-specific field for patients who want to track other systemic illnesses as well.

The correlation engine treats these as Tier B triggers: it surfaces the patient's personal pattern with explicit confidence bands, never overclaims, and labels the evidence tier on the trigger detail card. A patient who has had two SARS-CoV-2 infections and saw their rosacea worsen for several weeks after each will see that pattern in their personal data; a patient who has not seen any correlation will see the absence.

The educational copy on the trigger detail card surfaces the published evidence (Liu 2023, the 2025 cross-sectional) so the patient knows where the framing comes from. The framing is honest about the evidence tier: this is emerging, not canonical, and the patient's personal data is the cleanest answer to whether it applies to their case.

We will keep this article current as the literature evolves. New studies on post-COVID rosacea exacerbation are still being published; we expect the post-2025 literature to refine the prevalence estimates and the mechanism story. We will update the article when substantive new evidence lands.

What to bring up with your dermatologist

If your rosacea has worsened in a way you noticed after a SARS-CoV-2 infection or COVID-19 vaccination, the literature suggests you are not imagining the pattern. The exacerbation has been documented in published cohorts at meaningful prevalence rates.

What is useful to bring to a dermatologist visit:

- The approximate date of the infection or vaccination. The exacerbation typically presents within several weeks; the time anchor matters for the assessment. - A pre-event and post-event baseline of your rosacea severity. Per-feature, if possible (redness, papules, ocular involvement, sensory). The same per-feature framing that helps in any rosacea-tracking handoff (see our companion piece on what dermatologists actually want) makes the post-COVID question answerable. - The trajectory since the event. Did your rosacea stabilize at a new higher baseline, or has it gradually returned to the pre-event level? The Liu 2023 retrospective described patients in both patterns; your dermatologist's plan may differ depending on which trajectory you are on. - Other illnesses or interventions in the same window. If you had a SARS-CoV-2 infection in the same period that you started a new medication, switched topicals, or had a major life stressor, the dermatologist will want to disentangle the contributions. Logging the context helps.

The dermatology field is still working out the management story for post-COVID rosacea exacerbation specifically. There is not a settled protocol; the management is largely the same rosacea management as before, possibly with attention to the higher post-event baseline. The dermatologist is the right person to make those decisions. The patient's role, supported by the tracker, is to bring the timeline data that lets the conversation be precise rather than narrative.